ES8607312A1 - Un procedimiento para la preparacion de un compuesto seleccionado entre el grupo formado por los isomeros dextrogiros de espiro-hidantoinas asimetricas - Google Patents

Un procedimiento para la preparacion de un compuesto seleccionado entre el grupo formado por los isomeros dextrogiros de espiro-hidantoinas asimetricas

Info

Publication number
ES8607312A1
ES8607312A1 ES531873A ES531873A ES8607312A1 ES 8607312 A1 ES8607312 A1 ES 8607312A1 ES 531873 A ES531873 A ES 531873A ES 531873 A ES531873 A ES 531873A ES 8607312 A1 ES8607312 A1 ES 8607312A1
Authority
ES
Spain
Prior art keywords
derivatives
tritio
deutero
drug
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES531873A
Other languages
English (en)
Other versions
ES531873A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of ES8607312A1 publication Critical patent/ES8607312A1/es
Publication of ES531873A0 publication Critical patent/ES531873A0/es
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/96Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

PROCEDIMIENTO PARA LA OBTENCION DE LOS ISOMEROS DEXTROGIROS DE ESPIRO-HIDANTOINAS ASIMETRICAS Y DE SUS SALES BASICAS FISIOLOGICAMENTE COMPATIBLES, DE FORMULA (I), EN LA QUE X ES DEUTERIO, TRITIO O HALOGENO. CONSISTE EN LA REACCION DE HALOGENACION DE 4S-6-FLUOR-ESPIRO CROMAN-4,4K-IMIDAZOLIDIN-2,5K-DIONA EN LA POSICION 8 POR TRATAMIENTO CON FLUOR, CLORO O BROMO, EN UN DISOLVENTE INERTE A LA REACCION, A UNA TEMPERATURA COMPRENDIDA ENTRE C50JC Y 50JC; SEGUIDA DE LA REDUCCION CATALITICA DEL COMPUESTO OBTENIDO CON DEUTERIO O TRITIO, EN UN ALCANOL INFERIOR, EN PRESENCIA DE UN CATALIZADOR DE METAL NOBLE, COMO PALADIO. ESTOS COMPUESTOS TIENEN APLICACIONES FARMACOLOGICAS PARA EL TRATAMIENTO DE LAS COMPLICACIONES DE LA DIABETES CRONICA.
ES531873A 1983-04-27 1984-04-25 Un procedimiento para la preparacion de un compuesto seleccionado entre el grupo formado por los isomeros dextrogiros de espiro-hidantoinas asimetricas Expired ES8607312A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/488,947 US4474967A (en) 1983-04-27 1983-04-27 8-Deutero and 8-tritio-substituted derivatives of D-4S-6-fluoro-spiro-[chroman-4,4'-imidazolidine]-2',5'-dione

Publications (2)

Publication Number Publication Date
ES8607312A1 true ES8607312A1 (es) 1986-06-01
ES531873A0 ES531873A0 (es) 1986-06-01

Family

ID=23941785

Family Applications (1)

Application Number Title Priority Date Filing Date
ES531873A Expired ES8607312A1 (es) 1983-04-27 1984-04-25 Un procedimiento para la preparacion de un compuesto seleccionado entre el grupo formado por los isomeros dextrogiros de espiro-hidantoinas asimetricas

Country Status (22)

Country Link
US (1) US4474967A (es)
EP (1) EP0124327A3 (es)
JP (1) JPS59205384A (es)
KR (1) KR860000915B1 (es)
AU (1) AU542142B2 (es)
CA (1) CA1226866A (es)
CS (1) CS250661B2 (es)
DD (1) DD219772A5 (es)
DK (1) DK208284A (es)
ES (1) ES8607312A1 (es)
FI (1) FI841657A (es)
GR (1) GR81491B (es)
HU (1) HU191755B (es)
IL (1) IL71656A (es)
NO (1) NO841627L (es)
NZ (1) NZ207959A (es)
PH (1) PH22869A (es)
PL (1) PL142759B1 (es)
PT (1) PT78476B (es)
SU (1) SU1240362A3 (es)
YU (1) YU43358B (es)
ZA (1) ZA843091B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0172719B1 (en) * 1984-08-20 1988-09-21 Pfizer Inc. Process for the production as asymmetric hydantoins
US4841079A (en) * 1987-08-07 1989-06-20 Pfizer, Inc. Process for the production of asymmetric hydantoins
US5059693A (en) * 1989-10-06 1991-10-22 Pfizer Inc. Process for making 3-aroyl-2-oxindole-1-carboxamides
GB9317764D0 (en) * 1993-08-26 1993-10-13 Pfizer Ltd Therapeutic compound
ATE223219T1 (de) 1998-01-30 2002-09-15 R Tech Ueno Ltd Ophthalmische zubereitung

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3821383A (en) * 1972-07-10 1974-06-28 Ayerst Mckenna & Harrison Compositions for and a method of treating diabetic complications
US4117230A (en) * 1976-10-18 1978-09-26 Pfizer Inc. Hydantoin derivatives as therapeutic agents
CA1088945A (en) * 1976-10-18 1980-11-04 Pfizer Limited Hydantoin derivatives as therapeutic agents
US4130714A (en) * 1977-05-23 1978-12-19 Pfizer Inc. Hydantoin therapeutic agents
US4248882A (en) * 1980-02-12 1981-02-03 Pfizer Inc. Treating diabetes-associated complications with hydantoin amines
JPS5745185A (en) * 1980-07-21 1982-03-13 Eisai Co Ltd Hydantoin derivative and its preparation

Also Published As

Publication number Publication date
SU1240362A3 (ru) 1986-06-23
PH22869A (en) 1989-01-19
DK208284D0 (da) 1984-04-26
PT78476A (en) 1984-05-01
YU43358B (en) 1989-06-30
US4474967A (en) 1984-10-02
KR860000915B1 (ko) 1986-07-18
JPS59205384A (ja) 1984-11-20
EP0124327A2 (en) 1984-11-07
DK208284A (da) 1984-10-28
PT78476B (en) 1986-08-28
EP0124327A3 (en) 1985-07-31
CA1226866A (en) 1987-09-15
HUT34197A (en) 1985-02-28
ZA843091B (en) 1985-12-24
KR840008355A (ko) 1984-12-14
DD219772A5 (de) 1985-03-13
NO841627L (no) 1984-10-29
PL247379A1 (en) 1985-03-26
AU2726384A (en) 1984-11-01
HU191755B (en) 1987-04-28
FI841657A0 (fi) 1984-04-26
YU74184A (en) 1986-10-31
GR81491B (es) 1984-12-11
IL71656A (en) 1987-10-20
AU542142B2 (en) 1985-02-07
ES531873A0 (es) 1986-06-01
PL142759B1 (en) 1987-11-30
CS250661B2 (en) 1987-05-14
FI841657A (fi) 1984-10-28
IL71656A0 (en) 1984-07-31
NZ207959A (en) 1987-04-30

Similar Documents

Publication Publication Date Title
IE790088L (en) Thienohydantoin derivatives
DE3160449D1 (en) Hydantoin amines and pharmaceutical compositions thereof
ES8103058A1 (es) Un procedimiento para la preparacion de un derivado de imi- dazolidindiona
IE791592L (en) Spiro-oxazole derivatives
EP0249194A3 (en) Topical prostaglandin formulations
AU4242189A (en) Novel artemisinin derivatives, processes for their preparation and their use as antiprotozoal agents
IE792184L (en) Spiro-polycyclicimidazolidinedione derivatives
ES8607312A1 (es) Un procedimiento para la preparacion de un compuesto seleccionado entre el grupo formado por los isomeros dextrogiros de espiro-hidantoinas asimetricas
IE791540L (en) Spiro-furanohydantoin derivatives
IE792136L (en) Halogen-substituted benzopyran- and¹benzothiopyran-4-carboxylic acids
PT91612A (pt) Process for the preparation pf 2-aza-4(alkoxycarbonyl> spiro<4,5> decan-3-on and of his own acid derivative 1-(aminomethyl)-cyclo-hexane-acetic
AU2523588A (en) Mixture of substances for stabilyzing metabolism
AU1741288A (en) New polyoxygenated labdane derivatives, a process for their preparation, and their use as medicaments
DK250084D0 (da) Spiro-(imidazolidin-4,3'-indolin)-2,2',5-trionforbindelser og farmaceutisk praeparat indeholdende disse til behandling af med diabetes forbundne kroniske komplikationer
IE800109L (en) Spiro-quinolylhydantoins
KR890000156B1 (en) Hydantoin derivatives
CA2021923A1 (en) Pharmaceutical composition containing hydantoin derivative
AU6134786A (en) Adsorbent composition for lowering body alcohol content
Bartalena et al. Human hepatoma (Hep G2) cells secrete a novel T4-binding protein (27 K protein)

Legal Events

Date Code Title Description
MM4A Patent lapsed

Effective date: 19960401